Assessing BRCA carrier probabilities in extended families

Carlos H. Barcenas, G. M.Monawar Hosain, Banu Arun, Jihong Zong, Xiaojun Zhou, Jianfang Chen, Jill M. Cortada, Gordon Mills, Gail E. Tomlinson, Alexander R. Miller, Louise C. Strong, Christopher I. Amos

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Purpose: Carrier prediction models estimate the probability that a person has a BRCA mutation. We evaluated the accuracy of the BOADICEA model and compared its performance with that of other models (BRCAPRO, Myriad I and II, Couch, and Manchester Scoring System). We also studied the effect of extended family information on risk estimation using BOADICEA. Methods: We compared the area under receiver operating characteristic curves generated from 472 families with one member tested for BRCA mutations. We calculated sensitivity, specificity, and predictive values at an estimated probability of 10% and explored the biases of carrier prediction. Results; BOADICEA performed better than the other models in Ashkenazi Jewish (AJ) families, BRCAPRO performed slightly better in non-AJ families, and Myriad II performed comparably well in both groups. Including extended family information in BOADICEA yielded slightly better performance than did limiting the information to second-degree relatives. Using a 10% cutoff point, BOADICEA and Myriad II were most sensitive in predicting BRCA1/2 mutations in AJ families, and Myriad II was most sensitive in non-AJ families. The Manchester Scoring System was the most sensitive and least specific in a subgroup of non-AJ families. BOADICEA and BRCAPRO tended to underestimate the observed risk at low estimated probabilities and overestimate it at higher probabilities. Conclusion: The BOADICEA, BRCAPRO, and Myriad II models performed similarly. Including second-degree relatives slightly improved carrier prediction by BOADICEA. The Myriad II model was the easiest to implement.

Original languageEnglish (US)
Pages (from-to)354-360
Number of pages7
JournalJournal of Clinical Oncology
Volume24
Issue number3
DOIs
StatePublished - Jan 20 2006
Externally publishedYes

Fingerprint

Mutation
ROC Curve
Sensitivity and Specificity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Barcenas, C. H., Hosain, G. M. M., Arun, B., Zong, J., Zhou, X., Chen, J., ... Amos, C. I. (2006). Assessing BRCA carrier probabilities in extended families. Journal of Clinical Oncology, 24(3), 354-360. https://doi.org/10.1200/JCO.2005.02.2368

Assessing BRCA carrier probabilities in extended families. / Barcenas, Carlos H.; Hosain, G. M.Monawar; Arun, Banu; Zong, Jihong; Zhou, Xiaojun; Chen, Jianfang; Cortada, Jill M.; Mills, Gordon; Tomlinson, Gail E.; Miller, Alexander R.; Strong, Louise C.; Amos, Christopher I.

In: Journal of Clinical Oncology, Vol. 24, No. 3, 20.01.2006, p. 354-360.

Research output: Contribution to journalArticle

Barcenas, CH, Hosain, GMM, Arun, B, Zong, J, Zhou, X, Chen, J, Cortada, JM, Mills, G, Tomlinson, GE, Miller, AR, Strong, LC & Amos, CI 2006, 'Assessing BRCA carrier probabilities in extended families', Journal of Clinical Oncology, vol. 24, no. 3, pp. 354-360. https://doi.org/10.1200/JCO.2005.02.2368
Barcenas CH, Hosain GMM, Arun B, Zong J, Zhou X, Chen J et al. Assessing BRCA carrier probabilities in extended families. Journal of Clinical Oncology. 2006 Jan 20;24(3):354-360. https://doi.org/10.1200/JCO.2005.02.2368
Barcenas, Carlos H. ; Hosain, G. M.Monawar ; Arun, Banu ; Zong, Jihong ; Zhou, Xiaojun ; Chen, Jianfang ; Cortada, Jill M. ; Mills, Gordon ; Tomlinson, Gail E. ; Miller, Alexander R. ; Strong, Louise C. ; Amos, Christopher I. / Assessing BRCA carrier probabilities in extended families. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 3. pp. 354-360.
@article{69032fd5d9a24c139d09fc0c01296998,
title = "Assessing BRCA carrier probabilities in extended families",
abstract = "Purpose: Carrier prediction models estimate the probability that a person has a BRCA mutation. We evaluated the accuracy of the BOADICEA model and compared its performance with that of other models (BRCAPRO, Myriad I and II, Couch, and Manchester Scoring System). We also studied the effect of extended family information on risk estimation using BOADICEA. Methods: We compared the area under receiver operating characteristic curves generated from 472 families with one member tested for BRCA mutations. We calculated sensitivity, specificity, and predictive values at an estimated probability of 10{\%} and explored the biases of carrier prediction. Results; BOADICEA performed better than the other models in Ashkenazi Jewish (AJ) families, BRCAPRO performed slightly better in non-AJ families, and Myriad II performed comparably well in both groups. Including extended family information in BOADICEA yielded slightly better performance than did limiting the information to second-degree relatives. Using a 10{\%} cutoff point, BOADICEA and Myriad II were most sensitive in predicting BRCA1/2 mutations in AJ families, and Myriad II was most sensitive in non-AJ families. The Manchester Scoring System was the most sensitive and least specific in a subgroup of non-AJ families. BOADICEA and BRCAPRO tended to underestimate the observed risk at low estimated probabilities and overestimate it at higher probabilities. Conclusion: The BOADICEA, BRCAPRO, and Myriad II models performed similarly. Including second-degree relatives slightly improved carrier prediction by BOADICEA. The Myriad II model was the easiest to implement.",
author = "Barcenas, {Carlos H.} and Hosain, {G. M.Monawar} and Banu Arun and Jihong Zong and Xiaojun Zhou and Jianfang Chen and Cortada, {Jill M.} and Gordon Mills and Tomlinson, {Gail E.} and Miller, {Alexander R.} and Strong, {Louise C.} and Amos, {Christopher I.}",
year = "2006",
month = "1",
day = "20",
doi = "10.1200/JCO.2005.02.2368",
language = "English (US)",
volume = "24",
pages = "354--360",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Assessing BRCA carrier probabilities in extended families

AU - Barcenas, Carlos H.

AU - Hosain, G. M.Monawar

AU - Arun, Banu

AU - Zong, Jihong

AU - Zhou, Xiaojun

AU - Chen, Jianfang

AU - Cortada, Jill M.

AU - Mills, Gordon

AU - Tomlinson, Gail E.

AU - Miller, Alexander R.

AU - Strong, Louise C.

AU - Amos, Christopher I.

PY - 2006/1/20

Y1 - 2006/1/20

N2 - Purpose: Carrier prediction models estimate the probability that a person has a BRCA mutation. We evaluated the accuracy of the BOADICEA model and compared its performance with that of other models (BRCAPRO, Myriad I and II, Couch, and Manchester Scoring System). We also studied the effect of extended family information on risk estimation using BOADICEA. Methods: We compared the area under receiver operating characteristic curves generated from 472 families with one member tested for BRCA mutations. We calculated sensitivity, specificity, and predictive values at an estimated probability of 10% and explored the biases of carrier prediction. Results; BOADICEA performed better than the other models in Ashkenazi Jewish (AJ) families, BRCAPRO performed slightly better in non-AJ families, and Myriad II performed comparably well in both groups. Including extended family information in BOADICEA yielded slightly better performance than did limiting the information to second-degree relatives. Using a 10% cutoff point, BOADICEA and Myriad II were most sensitive in predicting BRCA1/2 mutations in AJ families, and Myriad II was most sensitive in non-AJ families. The Manchester Scoring System was the most sensitive and least specific in a subgroup of non-AJ families. BOADICEA and BRCAPRO tended to underestimate the observed risk at low estimated probabilities and overestimate it at higher probabilities. Conclusion: The BOADICEA, BRCAPRO, and Myriad II models performed similarly. Including second-degree relatives slightly improved carrier prediction by BOADICEA. The Myriad II model was the easiest to implement.

AB - Purpose: Carrier prediction models estimate the probability that a person has a BRCA mutation. We evaluated the accuracy of the BOADICEA model and compared its performance with that of other models (BRCAPRO, Myriad I and II, Couch, and Manchester Scoring System). We also studied the effect of extended family information on risk estimation using BOADICEA. Methods: We compared the area under receiver operating characteristic curves generated from 472 families with one member tested for BRCA mutations. We calculated sensitivity, specificity, and predictive values at an estimated probability of 10% and explored the biases of carrier prediction. Results; BOADICEA performed better than the other models in Ashkenazi Jewish (AJ) families, BRCAPRO performed slightly better in non-AJ families, and Myriad II performed comparably well in both groups. Including extended family information in BOADICEA yielded slightly better performance than did limiting the information to second-degree relatives. Using a 10% cutoff point, BOADICEA and Myriad II were most sensitive in predicting BRCA1/2 mutations in AJ families, and Myriad II was most sensitive in non-AJ families. The Manchester Scoring System was the most sensitive and least specific in a subgroup of non-AJ families. BOADICEA and BRCAPRO tended to underestimate the observed risk at low estimated probabilities and overestimate it at higher probabilities. Conclusion: The BOADICEA, BRCAPRO, and Myriad II models performed similarly. Including second-degree relatives slightly improved carrier prediction by BOADICEA. The Myriad II model was the easiest to implement.

UR - http://www.scopus.com/inward/record.url?scp=33644844013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644844013&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.02.2368

DO - 10.1200/JCO.2005.02.2368

M3 - Article

C2 - 16421416

AN - SCOPUS:33644844013

VL - 24

SP - 354

EP - 360

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -